David Dai Analyst Performance

Director, Senior Biotech Analyst at UBS Group

David Dai is a stock analyst at UBS Group, covering 7 publicly traded companies across a range of sectors. Over the past year, David Dai has issued 6 stock ratings, including buy and hold recommendations. While full access to David Dai's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights David Dai's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rating: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 7 Last 5 Years
Buy Recommendations: 71.43% 5 Buy Ratings
Companies Covered: 7 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	71.4%	5 ratings
Hold	28.6%	2 ratings
Sell	0.0%	0 ratings

Out of 7 total stock ratings issued by David Dai at UBS Group, the majority (71.4%) have been Buy recommendations, followed by 28.6% Hold.

Best & Worst Calls

Best Call
000.0%
BIDU
Apr 2020
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	100.0% of companies on NASDAQ	7 companies

David Dai, an analyst at UBS Group, currently covers 7 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 6 companies	85.7%
	Computer and Technology 1 company	14.3%

David Dai of UBS Group specializes in stock coverage within the Medical sector, with additional focus on Computer and Technology companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 5 companies	71.4%
MED - DRUGS 1 company	14.3%
INTERNET SERVICES 1 company	14.3%

About David Dai

David Dai currently works at UBS Securities LLC, as Analyst from 2024. Mr. Dai also formerly worked at SMBC Nikko Securities America, Inc., as Vice President & Senior Biotech Analyst from 2021 to 2023, Jefferies LLC, as Associate from 2018 to 2019, and Barclays Capital, Inc., as Associate Vice President from 2019 to 2021. Mr. Dai received his undergraduate degree in 2006 from the University of British Columbia and Masters Business Admin degree in 2020 from The University of Chicago Booth School of Business.

Follow on LinkedIn

Time Frame

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
SNDX Syndax Pharmaceuticals	7/15/2025	Lower Price Target	$9.26	$35.00	Buy
NRIX Nurix Therapeutics	7/10/2025	Lower Price Target	$12.67	$26.00	Buy
SMMT Summit Therapeutics	7/1/2025	Initiated Coverage	$21.28	$30.00	Buy
BPMC Blueprint Medicines	6/5/2025	Boost Price Target	$128.10	$129.00	Neutral
IOVA Iovance Biotherapeutics	5/16/2025	Downgrade	$1.76	$2.00	Neutral
CGEM Cullinan Therapeutics	5/12/2025	Lower Price Target	$7.89	$24.00	Buy

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.